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52-3042/Copyright ª 2014, ChongqAbstract It is well recognized that transcription factor-induced iPSCs carry an aberrant genetic
and epigenetic makeup. However, it is not clear whether these defects are developed de novo
due to the reprogramming process or inherited from the somatic source cells. Ma and colleagues
presented convincing data that iPSCs derived through transcription factor over-expression carry
a higher incidence of the epigenetic flaws in comparisonwith those generated through SCNT. The
authors conclude that 1) the source of the epigenetic aberrations is more related to the repro-
gramming protocol, and less to the intrinsic abnormality of the somatic source cells; 2) SCNT
based protocol is superior to that involving a cocktail of transcription factors. These important
findings by Ma and colleagues will certainly steer future research towards understanding the
mechanisms underpinning the SCNTreprogramming.With these efforts awhole array of unknown
factors is expected to emerge,which regulate the onset of early embryonic development and can
be applied to induce iPSCs with a healthier epigenetic landscape.
Copyrightª 2014, ChongqingMedicalUniversity. Production andhosting by Elsevier B.V. All rights
reserved.Induced pluripotent stem cells (iPSCs) and their differen-
tiated derivatives hold great promise for future autologous
cell therapy and disease modeling. Since the breakthrough
discovery made by Yamanaka et al,1,2 much effort has been
devoted to study the biological property of iPSCs regarding
its genetic stability, epigenetic fitness, as well as the safety
and efficacy of its differentiated products in comparison
with embryonic stem cells (ESCs). It was well recognized
early on that transcription factor-induced iPSCs carry an
aberrant genetic and epigenetic makeup. However, it is not
clear whether these defects are developed de novo due to
the reprogramming process or inherited from the somatic
source cells.3 Accumulated experimental evidence in-
dicates that the major difference between iPSCs and ESCs isity of Chongqing Medical
014.08.002
ing Medical University. Productionthe incomplete removal of the epigenetic memory of so-
matic cells, which may negatively affect the pluripotency
and lineage potential of the iPSCs. On the other hand other
genetic and epigenetic aberrations of the iPSCs may jeop-
ardize the fidelity of the pathophysiological phenotype
when iPSCs are used for disease modeling. Furthermore,
one major safety concern over the present iPSC products is
their tumorigenic potential due to the oncogenic property
of the transcription factors used in the reprogramming
protocol and the significant similarities between iPSCs and
cancer cells with respect to overall gene expression profiles
and epigenetic signatures.4 It is apparent that an alterna-
tive reprogramming protocol, free of the previously
mentioned flaws, needs to be invented before rendering
iPSC products meaningful to future clinical therapy and
disease modeling. Towards that end Ma and colleagues
conducted a methodical study comparing transcriptionand hosting by Elsevier B.V. All rights reserved.
Editorial 5factor-induced reprogramming with that induced by so-
matic cell nuclear transfer (SCNT). In their research report
published recently in Nature.5 Ma and colleagues presented
convincing data that iPSCs derived through transcription
factor over-expression carry a higher incidence of the
epigenetic flaws in comparison with those generated
through SCNT. The authors conclude that 1) the source of
the epigenetic aberrations is more related to the reprog-
ramming protocol, and less to the intrinsic abnormality of
the somatic source cells; 2) SCNT based protocol is superior
to that involving a cocktail of transcription factors. Since
this study tested only one type of human cells with fetal
origin, these initial results have yet to be validated through
reprogramming studies of cells from multiple embryonic
and adult tissues. Nevertheless, these important findings by
Ma and colleagues will certainly steer future research to-
wards understanding the mechanisms underpinning the
SCNT reprogramming. With these efforts a whole array of
unknown factors is expected to emerge, which regulate the
onset of early embryonic development and can be applied
to induce iPSCs with a healthier epigenetic landscape.
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